ZIOPHARM, Inc. and Solasia Pharma K.K. Announce License and Collaboration Agreement for Darinaparsin in Asia
3/7/2011 10:32:35 AM
NEW YORK & TOKYO--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM’s darinaparsin product (Zinapar™ or ZIO-101) and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
comments powered by